Stock 6919 CALIWAY BIOPHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Caliway Biopharmaceuticals Co., Ltd.

Equities

6919

TW0006919004

End-of-day quote Taipei Exchange
Other stock markets
 03:30:00 23/05/2024 am IST 		5-day change 1st Jan Change
417.5 TWD -1.18% Intraday chart for Caliway Biopharmaceuticals Co., Ltd. +10.45% +118.30%
25/04 Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints CI
05/03 Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints
CI
Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease
MT
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease
CI
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug
MT
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
CI
Caliway Biopharmaceuticals Gets US FDA Nod for Phase 2 Trial of Dercum's Disease Drug
MT
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease
CI
Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding
CI
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study
CI
Caliway Biopharmaceuticals Completes Recruitment for Severe Cellulite Drug Study
MT
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7
CI
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite
CI
Caliway Biopharmaceuticals Co., Ltd.(TPEX:6919) added to S&P Global BMI Index
CI
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
CI
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6919 Stock
  4. News Caliway Biopharmaceuticals Co., Ltd.